AVITA Medical, Inc. (AVH.XA)
| Previous close | 2.7200 |
| Open | 2.6500 |
| Bid | 0.0000 x N/A |
| Ask | 2.6200 x N/A |
| Day's range | 2.6000 - 2.6600 |
| 52-week range | 2.3800 - 6.2650 |
| Volume | |
| Avg. volume | 24,157 |
| Market cap | N/A |
| Beta (5Y monthly) | 1.55 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.3010 |
| Earnings date | 08 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireAVITA Medical Achieves Milestone with First Case Using RECELL GO
Joseph M. Still Burn Center at Doctors Hospital of Augusta first to treat a patient using AVITA Medical’s FDA-Approved RECELL GO System for thermal burn wounds and full-thickness skin defectsVALENCIA, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced that the Joseph M. Still Burn Center at Doctors Hospital of Augu
GlobeNewswireAVITA Medical Announces FDA Approval of RECELL GO
VALENCIA, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced that the U.S. Food and Drug Administration (FDA) has approved its premarket approval (PMA) supplement for the RECELL GO™ System, its next-generation autologous cell harvesting device that harnesses the regenerative properties of a patient’s own skin to tre
- GlobeNewswire
AVITA Medical to Host Investor Webinar Briefing
VALENCIA, Calif., May 16, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, invites shareholders and prospective investors to attend its investor webinar briefing and presentation by Jim Corbett, Chief Executive Officer, and David O’Toole, Chief Financial Officer, on May 21, 2024, at 4:00 p.m. Pacific Daylight Time / May 22, 2024, at 9:00 a.m. Au
